TRASTUZUMAB DERUXTECAN

Information current as at: 1 April 2025

PBAC meeting date: December 2022
  • ok Submission received for December 2022 PBAC meeting
  • ok Opportunity for consumer comment
  • ok PBAC meeting
  • ok PBAC outcome published
  • blocked Lodgement of required documentation
  • blocked Agreement to listing arrangements
  • blocked Government processes
  • blocked Medicine listed on the PBS
Legend: ok Completed N In progress blocked Not applicable N Yet to commence

Submission Details

Brand name:
  • Enhertu®
Pharmaceutical company:
AstraZeneca Pty Ltd
Condition/indication:
(therapeutic use)
  • Breast cancer
PBAC Submission type:
New PBS listing (–)
Comment:
--
Public Summary Document:
PBAC Public Summary Documents – December 2022
Related medicines:

Progress Details

okSubmission received for:
December 2022 PBAC meeting
okOpportunity for consumer comment:
Open 30/03/2022 and close 25/05/2022 (see PBS Website)
okPBAC meeting:
Held on 07/12/2022
okPBAC outcome published:
Deferred (see PBAC Outcomes)
blockedLodgement of required documentation:
Not applicable
blockedAgreement to listing arrangements:
Not applicable
blockedGovernment processes:
Not applicable
blockedMedicine listed on the PBS:
Not applicable
Glossary

Case ID: a683

Page last updated: 02 May 2024

Return to the Medicine Status Listing
tagv.9.18